Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions.

@article{Angiolillo2010PlateletAD,
  title={Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions.},
  author={Dominick Joseph Angiolillo and Jos{\'e} Luis Lamas Ferreiro},
  journal={Revista espanola de cardiologia},
  year={2010},
  volume={63 1},
  pages={60-76}
}
Platelet P2Y12 receptor antagonism with clopidogrel has represented a major advancement in the pharmacological management of patients with atherothrombotic disease, in particular those with acute coronary syndromes and undergoing percutaneous coronary interventions. Despite the benefit associated with clopidogrel therapy in these high risk settings, laboratory and clinical experience have led to identify some of its caveats, among which its wide range of platelet inhibitory response is the most… CONTINUE READING
20 Citations
70 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 70 references

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

  • JM Siller-Matula, AO Spiel, IM Lang, G Kreiner, G Christ, B Jilma
  • Thromb Haemost
  • 2009

P 2 Y 12 Receptor Antagonists clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor : an analysis of two randomised trials

  • MS Faber, U Fuhr
  • Lancet
  • 2009

Similar Papers

Loading similar papers…